Kathy LaPorte

Kathy D.
LaPorte was the founder of New Leaf Venture Partners LLC, founded in 2005, holding the title of Partner.
Ms. LaPorte is also the founder of HealthTech Capital Co. Ms. LaPorte is currently Director at Aesthetic Sciences Corp.
and Precipio Diagnostics LLC.
Ms. LaPorte is Independent Director at Bolt Biotherapeutics, Inc. since 2020, Precipio, Inc. since 2018, CERo Therapeutics Holdings, Inc. since 2021, and Q32 Bio, Inc. since 2024.
Ms. LaPorte is Director at Elysium Therapeutics, Inc. since 2016, Q32 Bio Operations, Inc. since 2021, and D2G Oncology, Inc. since 2020.
Former positions include Chief Executive Officer at Nodality, Inc. from 2015 to 2016; Director at Cytyc Prenatal Products Corp., Onyx Pharmaceuticals, Inc., eHealth, Inc., Cellgate, Inc., Prometheus Laboratories, Inc., Pearl Therapeutics, Inc., and Western Association of Venture Capitalists (President).
Director at ISTA Pharmaceuticals, Inc. from 2002 to 2011; VNUS Medical Technologies, Inc. from 1997 to 2008; Transcept Pharmaceuticals, Inc. (Old) in 2009; Affymax, Inc. (Independent Director) from 2011 to 2013; eHealthInsurance Services, Inc. from 2000 to 2007; California Institute for Regenerative Medicine from 2014 to 2017; Transcept Pharma, Inc. (Independent Director) from 2011 to 2012; Phoenix Biotech Acquisition Corp.
(Independent Director) from 2021 to 2024; 89bio, Inc. (Independent Director) from 2021 to 2025; New Leaf Venture Partners LLC (Partner) from 2005 to 2011; Sprout Group (General Partner) from 1993 to 2004; Credit Suisse Securities (USA) LLC (General Partner) in 2005; Asset Management Co. (Principal) from 1987 to 1992; and Analyst at First Boston Corp.
Education included undergraduate degree from Yale University in 1983 and MBA from Stanford Graduate School of Business in 1987.